FGFR3 and lung adenocarcinoma: Briefly, among newly detected mutations in lung adenocarcinoma, AKT, BRAF, FGFR2, HRAS, and KIT mutations were detected in one sample (1.3%), MAP2K in two samples (2.6%), MET in 4 samples (5.9%), and FGFR3 in 5 samples (7.4%) (Figure 5 and Supplementary Table 3).